Skip to main content
FTHFaeth Therapeutics, Inc.Hold4.5·$7.88
HoldModerate Confidence
Investment thesis

Faeth Therapeutics sits below the platform's quality floor on cash-burn and Piotroski weakness, but extreme short interest and a wide analyst-implied upside create an asymmetric speculative setup typical of early-stage biotech.

Thesis pillars

  • Large Analyst Upside Favorable Asymmetry↓Deteriorating
  • Quality Below Floor Cash Burn↓Deteriorating
  • Extreme High Short Interest↓Deteriorating
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 5, 2026, based on the 10-K filed Mar 30, 2026· older than 90 days

Full reasoning →

Open full analysis

Faeth Therapeutics, Inc. (FTH) Stock Analysis

HoldVALUE-TRAP 1/5ValueModerate Confidence

Healthcare · Biotechnology

Hold if already holding. Not a fresh buy at $7.88, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIKTOR; DATA_ISSUE: analyst_target_implausible (raw $56.15 vs price $7.88 — ratio 7.1×). Rejected, falling back to technical TP..

Faeth Therapeutics, Inc. (formerly Sensei Biotherapeutics) is a clinical-stage biotechnology company developing PIKTOR, an oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, for endometrial and HR+/HER2- breast cancer, following its February 2026 acquisition of Faeth... Read more

$7.88+174.2% Upside to targetScore 4.5/10#204 of 240 Biotechnology
QualityF-score4 / 9FCF yield-0.68%
Stop $7.60Resistance target $21.61A.R:R 0.0:1
Analyst consensus$56.15+612.6%13 analysts with price targets
$21.61Resistance target
$7.88price
$56.15mean
$69

Hold if already holding. Not a fresh buy at $7.88, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIKTOR; DATA_ISSUE: analyst_target_implausible (raw $56.15 vs price $7.88 — ratio 7.1×). Rejected, falling back to technical TP.. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $204M below $400M minimum. Not in investable universe. Score 4.5/10, moderate confidence.

Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 87d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.

10-K grounded · weekly refresh

About Faeth Therapeutics, Inc.

About Faeth Therapeutics, Inc.

PIKTOR, Faeth Therapeutics' lead oral multi-node PI3K/AKT/mTOR pathway inhibitor, is being evaluated in an ongoing Phase 2 trial in second-line advanced endometrial cancer (FTH-PIK-201), with topline data expected by year-end 2026, following the company's February 2026 acquisition of Faeth Therapeutics and a concurrent $200 million private placement. The company, formerly Sensei Biotherapeutics, reported a net loss of $21.1 million in 2025 and an accumulated deficit of $283.1 million, and has not generated product revenue to date.

Faeth has not generated product revenue and funds its PIKTOR development primarily through equity financings, including the $200 million private placement completed alongside the February 2026 Faeth acquisition from a syndicate that included B Group Capital, Balyasny Asset Management, Cormorant Asset Management, RA Capital Management, and Vivo Capital. PIKTOR combines two independently dosed, orally administered inhibitors -- serabelisib (a PI3Kalpha inhibitor) and sapanisertib (an mTORC1/2 inhibitor) -- designed to suppress the PI3K/AKT/mTOR pathway at multiple nodes rather than the single node targeted by the five currently approved therapies in this class. The company relies on third parties to conduct its preclinical and clinical trials and was not involved in PIKTOR's early development, making it dependent on external parties having accurately generated and reported the asset's historical data. Near-term catalysts include topline Phase 2 endometrial cancer data (FTH-PIK-201) expected by year-end 2026 and initiation of a Phase 1b breast cancer trial (FTH-PIK-101) targeted for the first half of 2026.

Show full overview

Faeth's valuation rests almost entirely on one clinical-stage asset: PIKTOR is the company's sole named product candidate advancing through active trials, and a failure of either the Phase 2 endometrial readout or the planned Phase 1b breast cancer study to demonstrate safety and efficacy to regulators' satisfaction would leave the pipeline without a near-term alternative. That binary exposure is compounded by the company's post-acquisition history: Faeth (through predecessor Sensei) was not involved in PIKTOR's early development and depends on third parties having accurately generated, collected, and reported the preclinical and clinical data underlying the program to date.

See also: Healthcare · Biotechnology

From Faeth Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 16, 2026
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Feb 18, 202787d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Pipeline: PIKTOR
DATA_ISSUE: analyst_target_implausible (raw $56.15 vs price $7.88 — ratio 7.1×). Rejected, falling back to technical TP.
Market cap $204M below $400M minimum

Key Metrics

P/E (TTM)—
P/E (Fwd)-2.1
Mkt Cap$204M
EV/EBITDA-0.5
Profit Mgn0.0%
ROE-229.6%
Rev Growth—
Beta-0.18
DividendNone
Analysts with ratings19

Quality Signals

Piotroski F4/9

Options Flow

P/C20.00bearish
IV219%elevated

Concentration Risks(10-K Item 1A)

  • HIGHpipelinePIKTOR
    10-K Item 1: 'Following the Acquisition, our lead program is PIKTOR, an investigational multi-node inhibitor, or MNI, of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer'

Material Events(8-K, last 90d)

  • 2026-06-15Item 5.02MEDIUM
    The Board appointed Anand Parikh, currently the Company's Chief Operating Officer, as President and Chief Executive Officer effective June 13, 2026. No prior CEO departure reason cited in the excerpt provided.
    SEC filing →
  • 2026-06-15Item 1.02LOW
    On June 10, 2026, the Company terminated its 2022 at-the-market Sales Agreement with Jefferies LLC (up to $50 million), effective immediately; no shares were ever sold under the agreement prior to termination.
    SEC filing →
  • 2026-04-16Item 5.02MEDIUM
    Directors Christopher W. Gerry, Thomas Ricks, and Kristian Humer tendered conditional resignations effective two business days after the June 10, 2026 Annual Meeting, contingent on stockholder approval of a Series B preferred conversion (resulting in a Nasdaq change-of-control) and a charter amendment raising authorized shares from 12,500,000 to 300,000,000.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

4 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.4
Obv
1.0
Ma Position
2.2
Rsi
3.0
Capitulation risk (RSI 19, below 200MA)Volume distribution (falling OBV)Below 200-MA but MA still rising (+4.0%/30d) — pullback in uptrend, not confirmed weakness

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roa
0.0
Gross Margin
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
4.4
Moat
4.8
Current Ratio
5.0
Cash-burning (FCF negative)No competitive moatQuality concerns

Volatile — 28.1% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Put Call
0.0
Implied Vol
0.0
Days To Cover
2.9
Short Interest
4.6
Debt Equity
10.0
Elevated put/call: 20.00High IV: 219%Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
0.0
Earnings History
3.3
Erm
5.0
Earnings Timing
5.0
Earnings concerns: 2B/2M
GatesMomentum 1.3<4.5A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Executive change: officer departure/appointmentInsider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 87d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
19 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $7.84Resistance $22.05

Price Targets

$8
$22
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! DATA_ISSUE: analyst_target_implausible (raw $56.15 vs price $7.88 — ratio 7.1×). Rejected, falling back to technical TP.
! Market cap $204M below $400M minimum
! momentum at 1.3 (below the engine's 4.5 threshold)

Earnings

B
B
M
M
2/4 beats
Next Earnings2027-02-18 (87d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is FTH stock a buy right now?

Hold if already holding. Not a fresh buy at $7.88, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIKTOR; DATA_ISSUE: analyst_target_implausible (raw $56.15 vs price $7.88 — ratio 7.1×). Rejected, falling back to technical TP.. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $204M below $400M minimum. Not in investable universe. Resistance target $21.61 (+174.2%), stop $7.60 (−3.7%), A.R:R 0.0:1. Score 4.5/10, moderate confidence.

What is the FTH stock price target?

Resistance target: $21.61 (+174.2% upside). Resistance target $21.61 (+174.2%), stop $7.60 (−3.7%), A.R:R 0.0:1. Stop-loss: $7.60.

What are the risks of investing in FTH?

Concentration risk — Pipeline: PIKTOR; DATA_ISSUE: analyst_target_implausible (raw $56.15 vs price $7.88 — ratio 7.1×). Rejected, falling back to technical TP.; Market cap $204M below $400M minimum.

Is FTH overvalued or undervalued?

Faeth Therapeutics, Inc. trades at a P/E of N/A (forward -2.1). TrendMatrix value score: 5.0/10. Verdict: Hold.

What do analysts say about FTH?

19 analysts rate FTH, with a consensus score of 4.3/5. 13 analysts publish price targets averaging $56.

What does Faeth Therapeutics, Inc. do?Faeth Therapeutics, Inc. (formerly Sensei Biotherapeutics) is a clinical-stage biotechnology company developing PIKTOR,...

Faeth Therapeutics, Inc. (formerly Sensei Biotherapeutics) is a clinical-stage biotechnology company developing PIKTOR, an oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, for endometrial and HR+/HER2- breast cancer, following its February 2026 acquisition of Faeth Therapeutics. The company raised $200 million in gross proceeds from a concurrent private placement, reported a net loss of $21.1 million in 2025 and an accumulated deficit of $283.1 million, and has not generated product revenue.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · ADRX (ADARx Pharmaceuticals, Inc.) · HRMY (Harmony Biosciences Holdings, I) · MGTX (MeiraGTx Holdings plc)
Home › Stocks › FTH

Latest news

Latest News

Benzinga6d ago
Benzinga6d ago
Benzinga6d ago
Benzinga12d ago
Benzinga13d ago
Benzinga13d ago
Benzinga13d ago
Benzinga13d ago
Benzinga13d ago
Benzinga13d ago
Benzinga16d ago
Benzinga16d ago
Benzinga18d agoAnalyst
Benzinga19d ago
Fiscal.ai26d agoLeadership Change
Benzinga26d agoAnalyst
Fiscal.ai33d ago
Benzinga37d ago
Benzinga74d ago
Benzinga93d agoAnalyst
Loading more...